WO2007071092A1 - Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne - Google Patents

Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne Download PDF

Info

Publication number
WO2007071092A1
WO2007071092A1 PCT/CH2006/000716 CH2006000716W WO2007071092A1 WO 2007071092 A1 WO2007071092 A1 WO 2007071092A1 CH 2006000716 W CH2006000716 W CH 2006000716W WO 2007071092 A1 WO2007071092 A1 WO 2007071092A1
Authority
WO
WIPO (PCT)
Prior art keywords
radiation
blood
terahertz
frequencies
liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CH2006/000716
Other languages
English (en)
Inventor
Richard John Artley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ETeCH AG
Original Assignee
ETeCH AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ETeCH AG filed Critical ETeCH AG
Publication of WO2007071092A1 publication Critical patent/WO2007071092A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/0507—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
    • G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
    • G01N21/3581—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using far infrared light; using Terahertz radiation

Definitions

  • the invention relates to a non-invasive blood glucose sensor.
  • Diabetes is a disease of growing consequence.
  • a 2002 survey found that there were approximately 150 million diabetics in the world and it is estimated that there will be as many as 300 mil- lion by 2025. According to the American Diabetes Association, there are 16 million individuals in the U.S. who have diabetes.
  • the FDA has approved only one truly non-invasive blood glucose monitoring device: The GlucoWatch G2 Biographer, manufactured by Cygnus Inc., approved to detect glu- cose level trends and track patterns in people with diabetes (it must be used along with conventional blood glucose monitoring of blood samples) .
  • the device which looks like a wristwatch, pulls body fluid (interstitial fluid) from the skin using small electric currents . It can provide six measurements per hour for 13 hours.
  • the Medtronic MiniMed also FDA approved, involves placing a subcutaneous sensor and then having this interface with a remote-readable 'black box' . This is not truly non-invasive, does not provide continuous measurements, works only for 3 days, and needs to be used with a docking station to read-out.
  • Medtronic MiniMed uses a subcutaneously placed probe and runs for 3 days.
  • a wristwatch-style device from Glucon Inc. uses tiny lasers that resonate with blood glucose to pro- prise ultrasound and give 24-hour measurements (photo-acoustic: origin Tel Aviv University: US patent granted Feb. 2005 for "the use of photoacoustic waves originating in the blood vessel to calculate the concentration of glucose in the blood vessel") . Also important is the location or measurement of blood volume to be able to measure concentration.
  • Glucon "uses the acoustics e- lement to localize measured volume inside a blood vessel, as well as removing the influence of the outer layers of the skin, and the optics element provides the specificity to glucose by using several light wavelengths" . It claims to be as accurate as skin pricking, and is in the process of clinical trials and approval by the FDA. Launch ⁇ 2008, anticipated price >$1700.
  • Hitachi has determined that it is possible to compute the level of blood sugar by measuring parameters such as the thermal energy generated by metabolic reactions, the level of oxygen saturation of hemoglobin, and blood flow.
  • the device is undergoing clinical testing to support a premarket submission to the FDA and the Japan Ministry of Health, Labour and Welfare. Plans call for the device to go on sale in 2005, subject to regulatory approval .
  • GlucoStats System (Singapore) have non-invasive IR probes: currently undergoing clinical trials.
  • the present invention is characterized in that it combines the use of terahertz radiation and the use of infra-red radiation for detecting blood glucose and measuring its concentration by means of a multi-frequency radiation analysis, the radiation be- ing measured in reflected mode as well as potentially in transmitted and absorptive modes . It thus provides a more accurate reading than that possible with the use of any narrower frequency band such as IR or terahertz alone.
  • terahertz radiation alone for detecting blood glucose is, rather surprisingly, not immediately identifiable in the EPO database. However this is not considered to be novel, since two companies have been identified which have targeted terahertz radiation as a means of detecting blood glucose.
  • Spire 1 S quantum cascade laser device consists of hundreds of nanometer-thick gallium arsenide-based layers. Terahertz radia- tion has wavelengths that are longer than visible and infrared, but shorter than microwaves, and may be the only radiation source that can separate glucose from other substances .
  • Spire ' s terahertz quantum cascade laser instrument eliminates the need to draw blood samples by finger pricking . Thus , Spire ' s painless, non-invasive method of glucose detection using terahertz radiation may encourage diabetics to monitor their blood sugar levels more frequently' .
  • Spire will synthesize a number of phantom samples containing various glucose concentrations, as well as samples containing potentially competing species such as sucrose and fructose, and measure their optical characteristics with terahertz radiation.
  • the terahertz measurements will be carried out with the assistance of Dr. Tatiana Globus, Research Associate Professor in the Department of Electrical and Computer Engineering at the University of Virginia, at the Brookhaven National Laboratory in Upton, New York. Terahertz devices will be incorporated into a demonstration glucose monitoring instrument during Phase II of the development project' .
  • Teraview (Cambridge, UK) also has aspira- tions towards using terahertz radiation for non-invasive blood glucose sensing, but it has made no recent announcements (since 2002) on this. Teraview has some 31 patents, but none specifically mentions x blood' or 'glucose' .
  • That blood glucose has a distinctive IR spectrum is known from recent work in Fourier-transform infrared (FTIR) spectroscopy by Yaochun Shen at the Cavendish Laboratories, University of Cambridge .
  • FTIR Fourier-transform infrared
  • the project developed infrared assays for the biomedical analysis of blood samples by mid-IR spectroscopy to determine blood glucose, cholesterol, urea, total protein, triglycerides and creatinine, but not similar analysis means in- corporating teraHertz measurements.
  • Infra-red light emitting diodes capable of emitting different frequencies of infra-red radiation.
  • Terahertz light-emitting-diodes capable of emitting different frequencies of terahertz radiation.
  • Terahertz emission is capable of penetrating skin non-invasively to register subcutaneous structures.
  • the advantage utilized in the present invention is a small, cheap emitter device (LED type) , hitherto not achieved: it is tuneable, by magnetic field, and thus able to scan across a range of frequencies .
  • LED type emitter device
  • 4.) The knowledge of the 'signature' spectrum on glucose and other components of interest in the terahertz region and how these can be distinguished from other blood component spectra.
  • Multi-frequency scanning analysis technology which is capable of being trained to look for 'signatures' of specific compounds in the IR-to-microwave spectrum (and beyond) . This has been used in the IR and the microwave region for various uses including the detection of CJD prions in blood supplies, and in the IR to UV region for imaging historic documents such as the Dead Sea Scrolls. Multi-frequency scanning in the terahertz region (alone) has been used for explosives and prohibited substances detection: it has not hitherto been used in combination with other non-terahertz frequencies for blood glucose or other blood component detection.
  • the technology involves the testing of samples with different frequencies / wavelengths of radiation, measuring (or imaging) the reflected signal digitally, and then combining these digital data to provide a composite where the presence or absence of a signal is dependant upon data taken at more than one frequency / wavelength.
  • Patentable features claimed are the particular components, frequencies and algorithms used.
  • This method can be made into a hand-held home-use product containing at least IR and terahertz LED emitters, a reflective multi-frequency sensor, and appropriate detection software.
  • a device can in principle be used for continuous use if appropriately configured as a wristwatch- or similar type device. Such a device could be used in conjunction with other monitoring systems .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Emergency Medicine (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

L’invention concerne une méthode pour mesurer la concentration de composants sanguins tel que, mais non limités au glucose sanguin de manière non envahissante qui consiste à employer la mesure et l’analyse de spectres qui incluent, mais non limités aux spectres de réflectance dans au moins les régions infrarouge et térahertzienne du spectre électromagnétique, dans chaque cas dans une fourchette de fréquences, ou à au moins plusieurs fréquences significatives.
PCT/CH2006/000716 2005-12-21 2006-12-20 Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne Ceased WO2007071092A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75206205P 2005-12-21 2005-12-21
US60/752,062 2005-12-21

Publications (1)

Publication Number Publication Date
WO2007071092A1 true WO2007071092A1 (fr) 2007-06-28

Family

ID=37770818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2006/000716 Ceased WO2007071092A1 (fr) 2005-12-21 2006-12-20 Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne

Country Status (1)

Country Link
WO (1) WO2007071092A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873207A (zh) * 2015-05-15 2015-09-02 深圳市一体太糖科技有限公司 一种太赫兹连续血糖测量系统
CN105486731A (zh) * 2015-08-12 2016-04-13 成都市亿泰科技有限公司 基于太赫兹增强的无创血糖检测探头
US10568584B2 (en) 2015-11-30 2020-02-25 Samsung Electronics Co., Ltd. Apparatus for estimating blood component level using spectrum analysis
CN114727776A (zh) * 2019-09-30 2022-07-08 茵斯普瑞提股份公司 用于无创确定分析物的装置和方法
US12017216B2 (en) 2020-01-10 2024-06-25 Roche Diagnostics Operations, Inc. Method and laboratory system to process a laboratory carrier based on a feature of a test liquid in the laboratory carrier

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5313941A (en) * 1993-01-28 1994-05-24 Braig James R Noninvasive pulsed infrared spectrophotometer
US5452716A (en) * 1992-02-25 1995-09-26 Novo Nordisk A/S Method and device for in vivo measuring the concentration of a substance in the blood
GB2360842A (en) * 2000-03-31 2001-10-03 Toshiba Res Europ Ltd Investigating a sample using electromagnetic radiation
WO2003069318A2 (fr) * 2002-02-15 2003-08-21 Teraview Limited Analyseur et procede correspondant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5452716A (en) * 1992-02-25 1995-09-26 Novo Nordisk A/S Method and device for in vivo measuring the concentration of a substance in the blood
US5313941A (en) * 1993-01-28 1994-05-24 Braig James R Noninvasive pulsed infrared spectrophotometer
GB2360842A (en) * 2000-03-31 2001-10-03 Toshiba Res Europ Ltd Investigating a sample using electromagnetic radiation
WO2003069318A2 (fr) * 2002-02-15 2003-08-21 Teraview Limited Analyseur et procede correspondant

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COMPOUND SEMICONDUCTOR.NET: "Spire hopes to ease diabetics' lives", 24 August 2004 (2004-08-24), XP002425058, Retrieved from the Internet <URL:http://compoundsemiconductor.net/articles/news/8/8/19/1> [retrieved on 20070315] *
GILWON YOON ET AL: "Reagentless/non-invasive diagnosis of blood substances", LASERS AND ELECTRO-OPTICS, 2001. CLEO/PACIFIC RIM 2001. THE 4TH PACIFIC RIM CONFERENCE ON 15-19 JULY 2001, PISCATAWAY, NJ, USA,IEEE, vol. 1, 15 July 2001 (2001-07-15), pages I226 - I227, XP010566095 *
MASAKAZU HINENO: "INFRARED SPECTRA AND NORMAL VIBRATIONS OF BETA-D-GLUCOPYRANOSE", CARBOHYDRATE RESEARCH, vol. 56, 1977, Amsterdam, pages 219 - 227, XP002425060 *
NISHIZAWA J -I ET AL: "Terahertz wave generation and Raman amplification in semiconductors", PROCEEDINGS OF THE SPIE - THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING SPIE-INT. SOC. OPT. ENG USA, vol. 5445, no. 1, 2004, pages 8 - 13, XP002425059, ISSN: 0277-786X *
VONACH R ET AL: "Application of mid-infrared transmission spectrometry to the direct determination of glucose in whole blood", APPL SPECTROSC; APPLIED SPECTROSCOPY JUN 1998 SOC FOR APPLIED SPECTROSCOPY, FREDERICK, MD, USA, vol. 52, no. 6, June 1998 (1998-06-01), pages 820 - 822, XP009080696 *
YOSHINAGA H ET AL: "Far Infrared Spectrograph for Use From the Prism Spectral Region to About 1 mm Wavelength", JOURNAL OF THE OPTICAL SOCIETY OF AMERICA USA, vol. 48, no. 5, May 1958 (1958-05-01), pages 315 - 323, XP009080573 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104873207A (zh) * 2015-05-15 2015-09-02 深圳市一体太糖科技有限公司 一种太赫兹连续血糖测量系统
CN105486731A (zh) * 2015-08-12 2016-04-13 成都市亿泰科技有限公司 基于太赫兹增强的无创血糖检测探头
US10568584B2 (en) 2015-11-30 2020-02-25 Samsung Electronics Co., Ltd. Apparatus for estimating blood component level using spectrum analysis
CN114727776A (zh) * 2019-09-30 2022-07-08 茵斯普瑞提股份公司 用于无创确定分析物的装置和方法
CN114727775A (zh) * 2019-09-30 2022-07-08 格鲁可特拉技术股份公司 葡萄糖的无创确定
JP2022549958A (ja) * 2019-09-30 2022-11-29 インスピリティー アー・ゲー 分析対象物を非侵襲的に測定するための装置および方法
JP2022549959A (ja) * 2019-09-30 2022-11-29 グルコ テラ テック アー・ゲー グルコースの非侵襲的な測定
JP7524314B2 (ja) 2019-09-30 2024-07-29 インスピリティー アー・ゲー 分析対象物を非侵襲的に測定するための装置および方法
JP7608445B2 (ja) 2019-09-30 2025-01-06 グルコ テラ テック アー・ゲー グルコースの非侵襲的な測定
US12458255B2 (en) 2019-09-30 2025-11-04 Inspirity Ag Device and method for the non-invasive determination of analytes
US12017216B2 (en) 2020-01-10 2024-06-25 Roche Diagnostics Operations, Inc. Method and laboratory system to process a laboratory carrier based on a feature of a test liquid in the laboratory carrier

Similar Documents

Publication Publication Date Title
Villena Gonzales et al. The progress of glucose monitoring—A review of invasive to minimally and non-invasive techniques, devices and sensors
Khalil Spectroscopic and clinical aspects of noninvasive glucose measurements
US20050054907A1 (en) Highly portable and wearable blood analyte measurement system
Yamakoshi et al. Pulse glucometry: a new approach for noninvasive blood glucose measurement using instantaneous differential near-infrared spectrophotometry
EP2207474B1 (fr) Capteur optique pour déterminer la concentration d&#39;une substance à analyser
US7729734B2 (en) Non-invasive biothermophotonic sensor for blood glucose monitoring
JP2021037321A (ja) 血中物質濃度測定装置及び導光部
US10499839B1 (en) Optimized biophotonic sensors
US20230277063A1 (en) Wearable spectrometer for biomolecule interrogation in biological tissue
US20180310880A1 (en) Methods for Reducing Noise in Optical Biological Sensors
CN105307568A (zh) 非侵入式血液分析
JPH05508336A (ja) 血糖値の非侵襲的測定
WO2004081524A2 (fr) Procede de pretraitement de donnees selon les sites de mesure pour etalonnage et prediction robustes
WO2012136982A1 (fr) Dispositif et procédé pour la détection d&#39;analytes sanguins
US8406839B2 (en) Method and apparatus for determining blood analytes
US20220354398A1 (en) Device, system and method for non-invasive monitoring of physiological measurements
Uwadaira et al. Noninvasive blood glucose measurement
CN204666826U (zh) 一种太赫兹连续安检成像装置
Losoya-Leal et al. State of the art and new perspectives in non-invasive glucose sensors
US20210275061A1 (en) Human gas sensing glucose monitoring and ketone fluctuation detection device
Ogunsanya et al. Design and development of a non-invasive glucometer system
Priyoti et al. Non-invasive blood glucose measurement using near infra-red spectroscopy
WO2007071092A1 (fr) Sonde de glucose sanguin basée sur la spectroscopie de réflexion ou de transmission à des fréquences dans la région térahertzienne et au delà de la région térahertzienne
KR100775669B1 (ko) 팔목 휴대용 무채혈 혈당측정 장치
Luong et al. Research and design a non-invasive blood glucose measuring module

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06817766

Country of ref document: EP

Kind code of ref document: A1